TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04163588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone
Description: Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loop Diuretics
Description: Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop Diuretics
Description: Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
Study: NCT00509301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I-chTNT-1/B MAB
Description: The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I-chTNT-1/B MAB
Description: The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131-I-chTNT-1/B MAB
Description: The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
Study: NCT00000136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet
Description: 60 mg/kg every 8 hours, 90 mg/kg/day
Study: NCT02606695

Intervention type: DEVICE
Intervention: NuvaMap O.R.
Description: Clinical imaging software used to assess intraoperative spinal alignment

Intervention type: DEVICE
Intervention: NuvaMap
Description: Clinical imaging software used to assess spinal alignment
Study: NCT02376829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign System
Description: The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
Study: NCT00000136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet
Description: 60 mg/kg every 8 hours, 90 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: 5 mg/kg every 12 hours, 5 mg/kg every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: 5 mg/kg every 12 hours, 5 mg/kg every 24 hours
Study: NCT04552405

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Anti-inflammatory Diet
Description: FAP individuals followed for 3 months a low-inflammatory diet
Study: NCT03719560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Systemic cytarabine
Study: NCT06688617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish Hand Massage
Description: Swedish technique hand massage: Effleurage-petrissage-friction-tapotement,-vibration-effleurage
Study: NCT01260831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of Bedside Paediatric Early Warning System
Description: The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
Study: NCT03116347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
Study: NCT01260831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Standard of Care
Description: Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
Study: NCT03773523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Study: NCT05772715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthosis + exercise therapy
Description: The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthosis
Description: The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
Study: NCT04116502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10mg of ruxolitinib twice daily (bd)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide
Description: Via standard hospital mechanisms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-Alpha
Description: Any formulation, via standard hospital mechanisms
Study: NCT03637868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Study: NCT00301067

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
Study: NCT03634540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets administered orally.
Study: NCT02582749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH agonist/antagonist
Description: Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH agonist/antagonist
Description: Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
Study: NCT03744169

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical exam
Description: Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chest x-ray
Description: Results of chest x-ray will be collected for comparison with ultrasound findings.
Study: NCT03466346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
Study: NCT04239274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial pulsed current stimulation
Description: Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-no stimulation
Description: Subjects in this arm will receive one session of sham for 20 minutes.
Study: NCT02481960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CM-BC2 Irinotecan drug-eluting bead
Study: NCT02086565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal training and home visits
Description: patient portal training and home visits by CHW to coordinate care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal training
Description: training in use of patient portal
Study: NCT01901471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single bolus of Placebo of CicloMulsion® (Neurovive).
Description: The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single bolus of cyclosporine A (CicloMulsion®, Neurovive)
Description: The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes.
Study: NCT03095183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grape flavored Puritan Junior tongue depressor

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional unflavored Puritan Regular Tongue Depressor
Study: NCT02535949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
Study: NCT03116347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KIOVIG
Description: 100 mg/ml solution for Immune Globulin Intravenous Infusion
Study: NCT02535949

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
Study: NCT00387660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT06690047

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ruconest
Description: recombinant human C1-esterase inhibitor
Study: NCT06689579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar hemiarthroplasty
Study: NCT01242215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: oral
Study: NCT02122185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
Study: NCT03949062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
Study: NCT03822949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Day Light
Description: Patients are exposed to daylight for up to 10 days prior to surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light
Description: Patients are exposed to placebo light for up to 10 days prior to surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICU Intense Light
Description: ICU Patients are exposed to daylight for up to 10 days after surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ICU Placebo light
Description: ICU Patients are exposed to placebo light for up to 10 days after surgery
Study: NCT03084562

Intervention type: OTHER
Intervention: collect examination time, functional and clinical tolerability
Description: Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist

Intervention type: OTHER
Intervention: collect examination time, functional and clinical tolerability
Description: Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist